Global average data suggest that the prevalence of male obesity is increasing and that its
prevalence in some regions of Western Europe, Japan, China, Korea and USA is higher …

Introduction: More than two-thirds of patients with type 1 diabetes (T1D) are overweight (OW)
and/or obese (OB) in the USA and Western Europe, resulting in insulin resistance as in type …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Purpose To evaluate the variables influencing the therapeutic choice toward oral versus
subcutaneous semaglutide in a cohort of diabetic subjects. Methods We retrospectively …

Context Combination therapy with insulin and glucagon-like peptide-1 receptor agonists
(GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy …

Background Management guidelines for obesity suggest maintaining a minimum of 5% body
weight reduction to help prevent or lower the risk of developing conditions such as …

Overweight and obesity are one of the most relevant health factors; according to the WHO,
39% of people globally are overweight and 13% obese. 1 Body weight loss of 3%–5% has …

Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

Importance No retrospective cohort study has assessed the effectiveness of semaglutide at
doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To …